Carl Laflamme, PhD

Dr. Laflamme is a cell biologist specializing in membrane trafficking in neurodegenerative diseases. He completed his PhD (2009–2015) with Gregory Emery at the University of Montréal, studying membrane trafficking in Drosophila. He then joined the laboratory of Peter McPherson at the Montreal Neurological Institute (The Neuro, McGill) as a postdoctoral fellow (2015–2022), where he developed an antibody characterization pipeline for C9orf72, the major protein associated with amyotrophic lateral sclerosis (ALS). Building on this work, he co-established the Antibody Characterization through Open Science (YCharOS) initiative in 2020, a public-private partnership dedicated to standardizing antibody characterization for neurodegenerative disease research. He is now an Academic Associate at The Neuro, where his team leverages selective and renewable antibodies to explore protein biology in ALS, Parkinson’s disease and Alzheimer’s disease.